studies

metastatic/advanced NSCLC (mNSCLC) - 1st line (L1), atezolizumab plus carboplatin plus paclitaxel vs. bevacizumab based treatment, meta-analysis of study results

OutcomeTE95% CInkI2ROBPub. bias deaths (OS)detailed resultsIMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 0.85 [0.71; 1.02] 0.85[0.71; 1.02]IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 201810%802NAnot evaluable progression or deaths (PFS)detailed resultsIMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 0.91 [0.78; 1.06] 0.91[0.78; 1.06]IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 201810%802NAnot evaluable objective responses (ORR)detailed resultsIMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 2018 1.02 [0.77; 1.35] 1.02[0.77; 1.35]IMpower-150 (ACP vs BCP ; all population, EXPLORATORY), 201810%794NAnot evaluable0.52.01.0relative treatment effectwww.metaEvidence.org2024-11-04 22:05 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 196,36,228,174,171,173,307,165,163,176,308,164,166,220 - treatments: 744